LE WE PMID CA
CNS (Neoplasia Glioma)1010ZNS (Neubildung Gliom)

Angiogenesis

Bevacizumab ttVEGF

Carmustine

CMV

CNS (Insula)

CNS (MRT)

CNS (Neoplasia Astrocytoma)

CNS (Neoplasia Glioblastoma)

CNS (Neoplasia Glioma)

CNS (Neoplasia Oligodendroglioma)

Galectin

Galectin1

Gliadel wafers

IDH1 Isocitrate dehydrogenase1 NADP soluble

IDH2

IETD ttCaspase9

Interleukin24 MDA7

JNK

LEHD ttCaspase9

Neoplasia (Invasion and metastasis)

Neoplasia (Oncolytic virus)

Neoplasia (Tumor biology and immunology)

Neurostatin

Notch

PDGF

PTEN MMAC1 TEP1

Radiation therapy

Radioprotector

Skin (Neoplasia Melanoma)

SP600125 ttJNK1 ttJNK2 ttJNK3

Stem cell (Embryonal)

Temozolomide

Vaccine (Oncology)

zVAD ttCaspases

2007  
1
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
[17999840] Health Technol Assess 11(45): iii-iv, ix-221 (2007)
2001  
2
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
[11359682] Health Technol Assess 5(13): 1-73 (2001)
2009  
3
Targeted therapy in the treatment of malignant gliomas.
[20616900] Onco Targets Ther 2(-): 115-33 (2009)
2010  
4
Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.
[20853178] Target Oncol 5(3): 183-91 (2010)
2010  
5
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas.
[20844972] Target Oncol 5(3): 193-200 (2010)
2010  
6
Targeted therapies on the horizon for malignant glioma.
[20827575] Target Oncol 5(3): 157-60 (2010)
2010  
7
Vascular endothelial growth factor inhibitors in malignant gliomas.
[20821351] Target Oncol 5(3): 167-74 (2010)
2010  
8
Targeting integrins in malignant glioma.
[20820929] Target Oncol 5(3): 175-81 (2010)
2010  
9
Molecular markers in gliomas: impact for the clinician.
[20809335] Target Oncol 5(3): 201-10 (2010)
2010  
10
Immune therapeutic targeting of glioma cancer stem cells.
[20737294] Target Oncol 5(3): 217-27 (2010)
2010  
11
Glioma stem cells as a target for treatment.
[20737293] Target Oncol 5(3): 211-5 (2010)
2010  
12
MGMT promoter methylation in malignant gliomas.
[20725792] Target Oncol 5(3): 161-5 (2010)
2007  
13
Lessons learned in the development of targeted therapy for malignant gliomas.
[17620423] Mol Cancer Ther 6(7): 1909-19 (2007)
2008  
14
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456781] Ann Oncol 19 Suppl 2(-): ii83-5 (2008)
2006  
15
Adjuvant treatment of high grade gliomas.
[17018721] Ann Oncol 17 Suppl 10(-): x186-90 (2006)
2006  
16
2002  
17
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
[11870527] Br J Cancer 86(4): 501-5 (2002)
2007  
18
Molecularly targeted therapy for malignant glioma.
[17520692] Cancer 110(1): 13-24 (2007)
2004  
19
Temozolomide in the treatment of recurrent malignant glioma.
[14745879] Cancer 100(3): 605-11 (2004)
2006  
20
Low-grade gliomas in adults.
[16794247] Oncologist 11(6): 681-93 (2006)
1999  
21
New treatment strategies for malignant gliomas.
[10394589] Oncologist 4(3): 209-24 (1999)
2009  
22
Angiocentric glioma: a case series.
[19338465] J Neurosurg Pediatr 3(3): 197-202 (2009)
2010  
23
Surgical management of World Health Organization Grade II gliomas in eloquent areas: the necessity of preserving a margin around functional structures.
[20121443] Neurosurg Focus 28(2): E8 (2010)
2009  
24
Embryological development of the human insula and its implications for the spread and resection of insular gliomas.
[19645558] Neurosurg Focus 27(2): E2 (2009)
2006  
25
Management of malignant glioma: steady progress with multimodal approaches.
[16709034] Neurosurg Focus 20(4): E3 (2006)
2003  
26
Pathology of low-grade gliomas: an update of emerging concepts.
[12816723] Neuro Oncol 5(3): 168-78 (2003)
2001  
27
From the archives of the AFIP: superficial gliomas: radiologic-pathologic correlation. Armed Forces Institute of Pathology.
[11706224] Radiographics 21(6): 1533-56 (2001)
2006  
28
Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging.
[16926329] Radiology 240(3): 803-10 (2006)
2010  
29
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555079] Ann Oncol 21 Suppl 5(-): v190-3 (2010)
2009  
30
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454432] Ann Oncol 20 Suppl 4(-): 126-8 (2009)
2010  
31
Gliomagenesis and the use of neural stem cells in brain tumor treatment.
[20184546] Anticancer Agents Med Chem 10(2): 121-30 (2010)
2008  
32
2010  
33
Molecular diagnostics of gliomas: state of the art.
[20714900] Acta Neuropathol 120(5): 567-84 (2010)
2010  
34
Protein tyrosine phosphatases in glioma biology.
[19936768] Acta Neuropathol 119(2): 157-75 (2010)
2010  
35
Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences.
[20089718] Radiology 254(3): 876-81 (2010)
2009  
36
Mutant metabolic enzymes are at the origin of gliomas.
[19996293] Cancer Res 69(24): 9157-9 (2009)
2010  
37
2009  
38
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.
[19951140] Expert Rev Neurother 9(12): 1815-36 (2009)
2007  
39
Insights into the cancer stem cell model of glioma tumorigenesis.
[17549283] Ann Acad Med Singapore 36(5): 352-7 (2007)
2007  
40
The role of surgery in high-grade glioma--is surgical resection justified? A review of the current knowledge.
[17549284] Ann Acad Med Singapore 36(5): 358-63 (2007)
2007  
41
Chemotherapy in adults with gliomas.
[17549285] Ann Acad Med Singapore 36(5): 364-6 (2007)
2009  
42
Molecularly targeted therapies for malignant gliomas.
[19148300] Mol Med 15(3-4): 115-22 (2009)
2009  
43
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
[19192961] Expert Rev Anticancer Ther 9(2): 235-45 (2009)
2004  
44
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
[15197348] Cancer Biol Ther 3(8): 739-51 (2004)
2003  
45
mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling.
[14508103] Cancer Biol Ther 2(4): 347-53 (2003)
2010  
46
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
[20523363] Cancer Gene Ther 17(9): 664-74 (2010)
2010  
47
New insights into susceptibility to glioma.
[20212223] Arch Neurol 67(3): 275-8 (2010)
2010  
48
Bevacizumab for malignant gliomas.
[20212225] Arch Neurol 67(3): 285-8 (2010)
2007  
49
Gliadel wafers in the treatment of malignant glioma: a systematic review.
[17938702] Curr Oncol 14(5): 189-94 (2007)
2009  
50
Current concepts and newer developments in the treatment of malignant gliomas.
[19346642] Indian J Cancer 46(2): 88-95 (2009)
2009  
51
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments.
[19346643] Indian J Cancer 46(2): 96-107 (2009)
2009  
52
Current concepts in the pathology and genetics of gliomas.
[19346644] Indian J Cancer 46(2): 108-19 (2009)
2010  
53
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
[20368564] J Clin Oncol 28(13): 2293-9 (2010)
2010  
54
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
[20445000] CA Cancer J Clin 60(3): 166-93 (2010)
2003  
55
Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression.
[12693889] Ann Intern Med 138(8): 659-68 (2003)
2011  
56
Platelet-derived growth factor receptor alpha in glioma: a bad seed.
[21880180] Chin J Cancer 30(9): 590-602 (2011)
2010  
57
Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.
[20414333] J Oncol 2010(-): 251231 (2010)
2010  
58
Molecular therapeutic targets for glioma angiogenesis.
[20414463] J Oncol 2010(-): 351908 (2010)
2010  
59
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
[20610347] Lancet Neurol 9(7): 717-26 (2010)
2011  
60
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.
[22084619] Clin Med Insights Oncol 5(-): 265-314 (2011)
2007  
61
Radiotherapeutic alternatives for previously irradiated recurrent gliomas.
[17760992] BMC Cancer 7(-): 167 (2007)
2010  
62
The pathobiology of glioma tumors.
[19737106] Annu Rev Pathol 5(-): 33-50 (2010)
2011  
63
Characterization of invading glioma cells using molecular analysis of leading-edge tissue.
[22102942] J Korean Neurosurg Soc 50(3): 157-65 (2011)
2011  
64
Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis.
[22030012] Herpesviridae 2(1): 10 (2011)
2009  
65
Advances in oncolytic virus therapy for glioma.
[19149710] Recent Pat CNS Drug Discov 4(1): 1-13 (2009)
2009  
66
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
[19381449] J Neurooncol 94(3): 299-312 (2009)
2011  
67
Advances in MRI assessment of gliomas and response to anti-VEGF therapy.
[21234719] Curr Neurol Neurosci Rep 11(3): 336-44 (2011)
2010  
68
2010  
69
The functional role of Notch signaling in human gliomas.
[20150387] Neuro Oncol 12(2): 199-211 (2010)
2009  
70
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
[19332770] Neuro Oncol 11(5): 550-5 (2009)
2010  
71
2010  
72
2009  
73
2011  
74
Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.
[21949569] World J Biol Chem 2(9): 193-201 (2011)
2009  
75
Immunotherapeutic approaches for glioma.
[19348609] Crit Rev Immunol 29(1): 1-42 (2009)
2011  
76
Clinical development of experimental therapies for malignant glioma.
[21509204] Sultan Qaboos Univ Med J 11(1): 5-28 (2011)
2009  
77
Current available therapies and future directions in the treatment of malignant gliomas.
[19707392] Biologics 3(-): 15-25 (2009)
2007  
78
GLIOGENE an International Consortium to Understand Familial Glioma.
[17855690] Cancer Epidemiol Biomarkers Prev 16(9): 1730-4 (2007)
2009  
79
Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
[19584260] Mol Cancer Res 7(7): 1000-12 (2009)
2009  
80
DNA repair and resistance of gliomas to chemotherapy and radiotherapy.
[19609002] Mol Cancer Res 7(7): 989-99 (2009)
2011  
81
Glutamate and the biology of gliomas.
[21192095] Glia 59(8): 1181-9 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Hochgradig maligne Gliome und Ponsgliome
  • Gliome niedrigen Malignitätsgrades im Kindes- und Jugendalter
  • Gliome


  • Search PubMed and many other databases on the combined search terms

    GG: glioma

  • ZNS (Neubildung Gliom)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia